Previous 10 | Next 10 |
home / stock / cphrf / cphrf news
Cipher Pharmaceuticals ( OTC:CPHRF ) reports that Bausch Health Companies (NYSE: BHC ) has notified it that it intends to terminate its license agreement for constipation med Trulance (plecanatide) due to an undisclosed breach of certain provisions of the contract. More news on: Cipher P...
Cipher Pharmaceuticals ( OTC:CPHRF ) has received a Notice of Termination from Bausch Health (NYSE: BHC ) in connection with the License, Development and Commercialization Agreement of Trulance® (plecanatide). More news on: Cipher Pharmaceuticals Inc., Bausch Health Companies Inc., ...
Cipher Pharmaceuticals Receives Notice of Termination from Bausch Canada NewsWire OAKVILLE, ON, Jan. 20, 2020 OAKVILLE, ON , Jan. 20, 2020 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the Company received a Notice of Term...
Cipher Pharmaceuticals Inc. (CPHRF) Q3 2019 Earnings Conference Call November 07, 2019 08:30 AM ET Company Participants Craig Mull - Interim Chief Executive Officer Nadine Jutlah - Interim Chief Financial Officer Conference Call Participants Prasath Pandurangan - Bloom Burton...
Cipher Pharmaceuticals ( OTC:CPHRF ): Q3 GAAP EPS of -$0.08 misses by $0.12 . More news on: Cipher Pharmaceuticals Inc., Earnings news and commentary, , Read more ...
Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results Canada NewsWire OAKVILLE, ON, Nov. 7, 2019 Revenue increased 20% to $5.8 million OAKVILLE, ON , Nov. 7, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announc...
Notice of Cipher Pharmaceuticals Q3 2019 Conference Call Canada NewsWire OAKVILLE, ON, Oct. 24, 2019 OAKVILLE, ON , Oct. 24, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced the details of its Q3 2019 financial results confer...
Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide) Canada NewsWire OAKVILLE, ON, Oct. 18, 2019 OAKVILLE, ON , Oct. 18, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it has received Heal...
With one product candidate at Phase 3 of development and expecting completion in early 2020, Aclaris Therapeutics ( ACRS ) is a name to be followed carefully. The Phase 3 trial is estimated to be completed on January 15, 2020. With that said, the company’s cash burn rate is very signifi...
Cipher Pharmaceuticals Inc. (OTC:CPHRF) Q2 2019 Earnings Conference Call August 9, 2019 8:30 AM ET Company Participants Craig Mull - Interim Chief Executive Officer Nadine Jutlah - Interim Chief Financial Officer Conference Call Participants Andre Uddin - Mackie Research ...
News, Short Squeeze, Breakout and More Instantly...
Companhia Siderurgica Paulista Nova Cosipa Company Name:
CPHRF Stock Symbol:
OTCMKTS Market:
Companhia Siderurgica Paulista Nova Cosipa Website:
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders Canada NewsWire MISSISSAUGA, ON , June 14, 2024 /CNW/ - Cipher Pharmaceuticals Inc . (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the "Company ") today announced that i...
Cipher Pharmaceuticals Reports First Quarter 2024 Results Canada NewsWire (All figures are presented in U.S. Dollars) Adjusted EBITDA in Q1 2024 was $3.6 million , an increase of 12.5% over Q1 2023 Epuris sales volumes grew 7.2% in the quarter over Q1 2023, c...
Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call Canada NewsWire MISSISSAUGA, ON , May 3, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) (" Cipher " or the " Company ") today announced that it will release ...